▶ GLP-2 · SUBTOPIC · DOSING LITERATURE
GLP-2 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of GLP-2. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for GLP-2 reports the following route(s) of administration: Subcutaneous (FDA-label). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of GLP-2.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for GLP-2 of approximately ~5 days. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of GLP-2. Refer to the original publication for full protocol detail.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022) reports the GLP-2 protocol used in GLP-2 Once Weekly for the Treatment of Obesity (SURMOUNT-1), published in N Engl J Med. See the source for the protocol-level dose range, frequency, and duration. link
- Frías JP, Davies MJ, Rosenstock J, et al. (2021) reports the GLP-2 protocol used in GLP-2 versus GLP-3 Once Weekly in Patients with Type 2 Diabetes (SURPASS-2), published in N Engl J Med. See the source for the protocol-level dose range, frequency, and duration. link
- Horn DB, Aronne LJ, Wharton S, et al. (2026) reports the GLP-2 protocol used in GLP-2 for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN), published in Lancet. PMID 42119587. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ GLP-2 vs GLP-3 · which is stronger?
Head-to-head data from SURPASS-2 show GLP-2 15 mg outperformed GLP-3 1 mg on HbA1c (-2.30% vs -1.86%) and produced larger weight loss. Comparisons at higher GLP-3 doses (2.4 mg) are also published; GLP-2 retains an edge on average.
▶ How is GLP-2 dosed?
Per FDA label, GLP-2 is titrated weekly: 2.5 mg starting → 5 mg → up to 15 mg over months. This wiki reproduces the label dose schedule for reference only; any human use should be under qualified clinical supervision.
▶ What is the half-life of GLP-2?
Approximately five days, enabled by a C20 fatty-acid linker on a modified GIP backbone that drives albumin binding and slow clearance.
▶ How quickly do you lose weight on GLP-2?
In SURMOUNT-1, mean weight loss followed a curve: ~2-3% by week 4, ~10% by week 24, ~20% by week 72 at the highest dose arm. Individual response varies significantly.
▶ Can GLP-2 be reconstituted from a research vial?
Yes. Reconstitute lyophilized GLP-2 with USP-grade sterile diluent. The PEPPUDEX /calculator returns the volume-per-dose math given vial size, diluent volume, and target dose.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 2–8 °C, manufacturer-label expiration
Reconstituted · 2–8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Approved as GLP-2 prescription analog (T2D, May 2022) and GLP-2 prescription analog (chronic weight management, Nov 2023). Compounded versions restricted since FDA shortage declaration lifted Oct 2024.
WADA · Not currently listed on the WADA Prohibited List (2026).
RELATED PAGES
▶ LAST UPDATED · 2026-05-19